Combinations of a vegf receptor inhibitor with other...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 45/06 (2006.01) A61P 3/00 (2006.01) A61P 9/00 (2006.01) A61P 27/00 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2539230

The invention relates to a combination therapy for treating patients suffering from diseases characterized by cell proliferation and infiltration of inflammatory cells, coronary diseases, hypertension, renal diseases, diabetes, or ocular diseases and conditions. The patient is treated with a combination of: (a) a VEGF inhibitor compound; and (b) one or more second therapeutic agents selected from the group consisting of: i. angiostatic steroids; ii. photosensitizers; iii. implants containing corticosteroids; iv. AT1 receptor antagonists; V. ACE inhibitors; vi. cyclooxygenase inhibitors; vii. IGF-IR inhibitors; viii. mTOR kinase inhibitors; ix. somatostatin receptor antagonists; X. P13K inhibitors; A. Raf kinase inhibitors; xii. PKC inhibitors; xiii. integrin antagonists; xiv. endogenous anti-anglogenic molecules; and xv. PEDF and analogs.

L'invention concerne une thérapie combinatoire utilisée dans le traitement de patients souffrant de maladies se caractérisant par la prolifération cellulaire et l'infiltration des cellules inflammatoires, de maladies coronariennes, d'hypertension, de maladies rénales, de diabètes, ou de maladies et d'états pathologiques occulaires. Le patient est traité au moyen d'une combinaison (a) d'un composé inhibiteur du VEGF et (b) d'un ou de plusieurs seconds agents thérapeutiques sélectionnés dans le groupe comprenant: i. les stéroïdes angiostatiques; ii. les photosensensibilisants; iii. les implants contenant des corticostéroïdes; iv. les antagonistes du récepteur AT1; v. les inhibiteurs d'ACE; vi. les inhibiteurs de la cyclooxygénase; vii. les inhibiteurs d'IGF-IR; viii. les inhibiteurs de la mTOR kinase; ix. les antagonistes du récepteur de la somatostatine; x. les inhibiteurs de P13K; xi. les inhibiteurs de la Raf kinase; xii. les inhibiteurs de PKC; xiii. les antagonistes de l'intégrine; xiv. des molécules endogènes anti-angiogéniques; et xv. le PEDF et ses analogues.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Combinations of a vegf receptor inhibitor with other... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combinations of a vegf receptor inhibitor with other..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combinations of a vegf receptor inhibitor with other... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2051151

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.